M. Sioud et M. Leirdal, Design of nuclease resistant protein kinase C alpha DNA enzymes with potential therapeutic application, J MOL BIOL, 296(3), 2000, pp. 937-947
For the therapeutic application of catalytic nucleic acids it is desirable
to have small, stable and inexpensive compounds that are active at physiolo
gical Mg2+ concentrations. We have explored the possibility of using the ve
rsatile 10-23 DNA catalytic core to suppress the expression of the protein
kinase C alpha (PKC alpha) isoform in malignant cells. By introducing eithe
r a 3'-3'-inverted thymidine nucleotide or site-specific phosphorothioate m
odification into a PKCa DNA enzyme, we have designed stable catalysts that
retained a significant in vitro cleavage activity. Ln particular, a DNA enz
yme containing phosphorothioate analogues in the antisense arms and in the
pyrimidine residues of the catalytic core was found to be remarkably stable
in 50 % human serum (t(1/2) > 90 hours) and inhibited in vitro cell growth
by up to 90 % at nanomolar concentrations. The inhibition of PKC alpha gen
e expression is sequence-specific, as a DNA enzyme with reversed antisense
arms was found to be ineffective. Epifluorescence microscopic analysis of c
ells transfected with a 5' fluorescein isothiocyanate-conjugated DNA enzyme
showed that the DNA enzyme molecules are mainly localised in the nuclei. M
ost of the DNA enzyme-treated cells were killed by apoptosis. The ability o
f the described PKC alpha DNA enzymes to trigger apoptosis (apoptozymes) in
malignant cells illustrates their therapeutic potential. Furthermore, such
agents can be a valuable tool for probing gene function. (C) 2000 Academic
Press.